Pulmonary embolism, coagulation
Zeile 43: | Zeile 43: | ||
{{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | {{tp|p=32338320|t=ä. Covid-19 treatment update: follow the scientific evidence |pdf=|usr=}} | ||
{{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}} | {{tp|p=32302456|t=2020. Potential of heparin and nafamostat combination therapy for COVID-19 |pdf=|usr=}} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− |
Version vom 11. Juni 2020, 10:49 Uhr
coviki.org collects the really good Ideas and the scientific Record on Covid-19 Virus.
Since there are many organ manifestations of Hypercoagulation, subcategorization and tranccategorization was applied.
- Venous thrombosis
- Pulmonary embolism
- Cerebral embolism
- Myocardial infarction
- Arterial embolism
- Microembolism
- Hypercoagulation
- Antiphospholipid antibodies
- Disseminated intravascular coagulation
- Bleeding
- Labwork of Thrombembolism
- Prophylaxis of Thrombembolism
The unifying concept behind is Dysendoheliosis with the components Coagulation /Microthrombi, proliferative or cytopathic obstructive Endotheliosis and mediator production as well as failure of the mitigating systems and secondary vasculitis.
- papers on various thromboembolic maifestations
32281926 2020. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)
32347323 ä. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation
32360371 ä. Thromboembolic events in patients with SARS-CoV-2
C7146714 ä. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32324101 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands
32133825 2020. Characteristics, causes, diagnosis and treatment of coagulation dysfunction in patients with COVID-19
32402423 2020. Ten key points that vascular doctors learned very quickly about COVID-19
32381264 2020. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis
32388068 2020. Thrombotic complications in critically ill patients with COVID 19
32291094 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19
32374544 2020. Risque thrombotique veineux induit par le SARS-CoV-2 : prevalence, recommandations et perspectives
- papers on Hypoxemia
32359410 ä. Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT
C7177114 2020. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes
32376101 2020. Association Between Hypoxemia and Mortality in Patients With COVID-19
32338320 ä. Covid-19 treatment update: follow the scientific evidence
32302456 2020. Potential of heparin and nafamostat combination therapy for COVID-19